Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

141. Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients: a pharmacoeconomic analysis

Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients: a pharmacoeconomic analysis Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients: a pharmacoeconomic analysis Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients: a pharmacoeconomic analysis Wilbur K, Lynd LD, Sadatsafavi M Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of low-dose unfractionated heparin versus low-molecular weight heparin (LMWH) for the prevention of venous thromboembolism, in patients hospitalised for non-surgical

2012 NHS Economic Evaluation Database.

142. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction (Full text)

Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction To assess the cost-effectiveness of bivalirudin versus heparin and glycoprotein IIb/IIIa inhibitor (H-GPI) in patients undergoing primary percutaneous coronary intervention (PPCI) for acute ST-segment elevation myocardial infarction (STEMI), from a UK health service perspective.Cost-utility analysis with life-long time horizon.Costs, quality

2012 EvidenceUpdates PubMed

143. Early intravenous unfractionated heparin and mortality in septic shock

Early intravenous unfractionated heparin and mortality in septic shock PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2012 PedsCCM Evidence-Based Journal Club

144. Oral Direct Factor Xa Inhibitors Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in Patients Undergoing Total Hip or Knee Replacement: A Systematic Review and Meta-analysis. (PubMed)

Oral Direct Factor Xa Inhibitors Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in Patients Undergoing Total Hip or Knee Replacement: A Systematic Review and Meta-analysis. Thromboembolic disease is the most frequent medical complication of arthroplasty.To evaluate the benefits and harms of oral direct factor Xa inhibitors versus low-molecular-weight heparin (LMWH) in patients undergoing total hip or knee replacement.MEDLINE (1966 to December 2011), EMBASE (1980

2012 Annals of Internal Medicine

145. A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients (PubMed)

A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients Central venous catheters (CVCs) are used for vascular access in hemodialysis patients who have no alternative access or are awaiting placement or maturation of a permanent access. The major complications of CVCs are catheter-related bloodstream infection and clotting in the catheter lumen.Parallel-group, randomized, multicenter clinical trial, with patients blinded (...) to study intervention.16 free-standing dialysis facilities in Northern California belonging to a single provider. 303 adult maintenance hemodialysis patients who were using a tunneled cuffed CVC for vascular access.The treatment group received an antibiotic lock containing gentamicin 320 μg/mL in 4% sodium citrate, whereas the control group received the standard catheter lock containing heparin 1,000 U/mL. Both groups received triple-antibiotic ointment on the catheter exit site during dressing changes

2012 EvidenceUpdates

146. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis

Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis Silvain J, Beygui F, Barthelemy O, Pollack C, Cohen M, Zeymer U, Huber (...) K, Goldstein P, Cayla G, Collet JP, Vicaut E, Montalescot G CRD summary The review concluded that enoxaparin seemed to be superior to unfractionated heparin in reducing mortality and bleeding outcomes during percutaneous coronary intervention, particularly for primary intervention in patients with ST elevation myocardial infarction. The authors' conclusions appear reasonable and are likely to be reliable. Authors' objectives To determine the efficacy and safety of enoxaparin compared

2012 DARE.

147. Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden

Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 NHS Economic Evaluation Database.

148. A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children

A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2012 PedsCCM Evidence-Based Journal Club

149. Diagnosis and management of Heparin induced thrombocytopenia: second edition

Diagnosis and management of Heparin induced thrombocytopenia: second edition Guidelines on the diagnosis and management of heparin‐induced thrombocytopenia: second edition - Watson - 2012 - British Journal of Haematology - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term The full text of this article hosted at iucr.org is unavailable due to technical difficulties. guideline Free Access Guidelines (...) on the diagnosis and management of heparin‐induced thrombocytopenia: second edition Corresponding Author Aberdeen Royal Infirmary, Aberdeen, UK Correspondence: Dr Henry Watson, British Society for Haematology, 100 White Lion Street, London, N1 9PF, UK. E‐mail: Royal Brompton Hospital, London, UK Oxford University Hospitals, Oxford, UK Corresponding Author Aberdeen Royal Infirmary, Aberdeen, UK Correspondence: Dr Henry Watson, British Society for Haematology, 100 White Lion Street, London, N1 9PF, UK. E‐mail

2012 British Committee for Standards in Haematology

150. [Heparin-bonded vascular prostheses for the treatment of peripheral artery disease]

[Heparin-bonded vascular prostheses for the treatment of peripheral artery disease] Prótesis vasculares recubiertas con heparina para el tratamiento de la enfermedad arterial periférica [Heparin-bonded vascular prostheses for the treatment of peripheral artery disease] Prótesis vasculares recubiertas con heparina para el tratamiento de la enfermedad arterial periférica [Heparin-bonded vascular prostheses for the treatment of peripheral artery disease] Pichon Riviere A, Augustovski F, Garcia (...) . [Heparin-bonded vascular prostheses for the treatment of peripheral artery disease] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rápida N°252. 2012 Authors' objectives To assess the evidence available on the safety, efficacy and other aspects related to coverage polices of the use of heparin-bonding vascular prosthesis for the treatment of peripheral artery occlusion. Authors' conclusions Short and long-term primary and secondary permeability rates

2012 Health Technology Assessment (HTA) Database.

151. Prophylaxis for thromboembolic disease with low molecular weight heparins in adult patients in home care

Prophylaxis for thromboembolic disease with low molecular weight heparins in adult patients in home care Profilaxis de enfermedad tromboembólica con heparinas de bajo peso molecular en pacientes adultos en internación domiciliaria [Prophylaxis for thromboembolic disease with low molecular weight heparins in adult patients in home care] Profilaxis de enfermedad tromboembólica con heparinas de bajo peso molecular en pacientes adultos en internación domiciliaria [Prophylaxis for thromboembolic (...) disease with low molecular weight heparins in adult patients in home care] Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Bardach A, Ciapponi A, Urtasun M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Bardach A, Ciapponi

2012 Health Technology Assessment (HTA) Database.

152. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. (Full text)

Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. To determine the efficacy and safety of enoxaparin compared with unfractionated heparin during percutaneous coronary intervention.Systematic review and meta-analysis.Medline and Cochrane database of systematic reviews, January 1996 to May 2011.Randomised and non-randomised studies comparing enoxaparin with unfractionated heparin during percutaneous (...) elevation acute coronary syndrome or stable patients scheduled for percutaneous coronary intervention. A total of 13,943 patients (45.0%) received enoxaparin and 17,023 (55.0%) unfractionated heparin. Enoxaparin was associated with significant reductions in death (relative risk 0.66, 95% confidence interval 0.57 to 0.76; P<0.001), the composite of death or myocardial infarction (0.68, 0.57 to 0.81; P<0.001), and complications of myocardial infarction (0.75, 0.6 to 0.85; P<0.001), and a reduction

2012 BMJ PubMed

153. Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices

Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices Ghanbari H, Saint Phard W, Al-Ameri H (...) . Authors' objectives To assess the efficacy and safety of perioperative heparin-based bridging therapy versus uninterrupted warfarin therapy in patients undergoing pacemaker or implantable cardioverter-defibrillator implantation. Searching MEDLINE (1950 to 2012), EMBASE (1988 to 2012), Cochrane Central Register of Controlled Trials (CENTRAL) (fourth quarter 2011) were searched for studies published in English. Search terms were reported. Reports presented at scientific meetings and relevant conference

2012 DARE.

154. Randomised controlled trial: Flushing of intravenous locks in neonates: no evidence that heparin improves patency compared with saline

Randomised controlled trial: Flushing of intravenous locks in neonates: no evidence that heparin improves patency compared with saline Flushing of intravenous locks in neonates: no evidence that heparin improves patency compared with saline | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Flushing of intravenous locks in neonates: no evidence that heparin improves patency compared with saline Article Text Child health Randomised controlled

2012 Evidence-Based Nursing

155. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction (Full text)

Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction Schwenkglenks M, Toward TJ, Plent (...) -segment elevation myocardial infarction. The authors' concluded that bivalirudin was a cost-effective alternative to heparin plus a glycoprotein IIb/IIIa inhibitor. UK clinical practice appeared to be slightly different to that used in the trial that supplied the data, but the results were robust and the authors' conclusions are appropriate. Type of economic evaluation Cost-utility analysis Study objective The objective was to assess the cost-effectiveness of bivalirudin, for patients receiving

2012 NHS Economic Evaluation Database. PubMed

156. A diagnosis of heparin-induced thrombocytopenia with combined clinical and laboratory methods in cardiothoracic surgical intensive care unit patients (Full text)

A diagnosis of heparin-induced thrombocytopenia with combined clinical and laboratory methods in cardiothoracic surgical intensive care unit patients Diagnosing postoperative heparin-induced thrombocytopenia (HIT) in cardiothoracic surgical patients is complicated because of the profound thrombocytopenia that occurs with cardiopulmonary bypass (CPB). CPB predisposes patients to develop a frequent incidence of antibodies directed against platelet factor 4 (PF4)/heparin complexes and HIT (...) . The sensitivity of readily available antibody immunoassays is high, but specificity is quite low. The use of both a clinical probability score and rapid laboratory immunoassay has been shown to increase specificity, which is of particular importance in the CPB setting. Prompt diagnosis is crucial because cessation of heparin and treatment with alternative anticoagulation can reduce the risk of thromboembolic events.We retrospectively reviewed records from cardiothoracic surgical patients whose serum

2012 EvidenceUpdates PubMed

157. Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review (PubMed)

Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review Post-thrombotic syndrome causes considerable morbidity. The Home-LITE study showed a lower incidence of post-thrombotic syndrome and venous ulcers after 3 months of treating deep vein thrombosis with the low-molecular-weight heparin tinzaparin versus oral anticoagulation. This systematic review examined whether long-term treatment of deep vein thrombosis using low-molecular-weight heparin, rather than (...) oral anticoagulation, reduces development of post-thrombotic syndrome.We identified 9 articles comparing treatment of deep vein thrombosis using long-term low-molecular-weight heparin with any comparator, which reported outcomes relevant to the post-thrombotic syndrome assessed ≥ 3 months post-deep vein thrombosis.Pooled analysis of 2 studies yielded an 87% risk reduction with low-molecular-weight heparin in the incidence of venous ulcers at ≥ 3 months (P = .019). One study showed an overall odds

2011 EvidenceUpdates

158. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes (Full text)

Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes Schwenkglenks M, Brazier JE (...) , Szucs TD, Fox KA Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of bivalirudin compared with heparin plus glycoprotein IIb/IIIa inhibitor in thienopyridine-treated patients with non-ST-segment

2011 NHS Economic Evaluation Database. PubMed

159. Heparin-binding protein: A diagnostic marker of acute bacterial meningitis (PubMed)

Heparin-binding protein: A diagnostic marker of acute bacterial meningitis The early detection of bacterial meningitis is crucial for successful outcome. Heparin-binding protein, a potent inducer of increased vascular permeability, is released from activated neutrophils in severe sepsis.In this study we investigated whether heparin-binding protein levels in cerebrospinal fluid could be used as a diagnostic marker for acute bacterial meningitis.One prospective and one retrospective patient (...) of heparin-binding protein, lactate, protein, glucose, neutrophils, and mononuclear cells. Heparin-binding protein levels were significantly higher (p < .01) in patients with acute bacterial meningitis (median 376 ng/mL, range 12-858 ng/mL) than in patients with viral central nervous system infection (median 4.7 ng/mL, range 3.0-41 ng/mL) or neuroborreliosis (median 3.6 ng/mL, range 3.2-10 ng/mL) or in control patients with a normal cerebrospinal fluid cell count (median 3.5 ng/mL, range 2.4-8.7 ng/mL

2011 EvidenceUpdates

160. A continuous heparin infusion does not prevent catheter-related thrombosis in infants after cardiac surgery

A continuous heparin infusion does not prevent catheter-related thrombosis in infants after cardiac surgery PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2011 PedsCCM Evidence-Based Journal Club